These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24107467)

  • 1. Development and validation of COMPASS: clinical evidence of orphan medicinal products - an assessment tool.
    Picavet E; Cassiman D; Aertgeerts B; Simoens S
    Orphanet J Rare Dis; 2013 Oct; 8():157. PubMed ID: 24107467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
    Joppi R; Bertele' V; Garattini S
    Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evidence for orphan medicinal products-a cause for concern?
    Picavet E; Cassiman D; Hollak CE; Maertens JA; Simoens S
    Orphanet J Rare Dis; 2013 Oct; 8():164. PubMed ID: 24131572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).
    Annemans L; Aymé S; Le Cam Y; Facey K; Gunther P; Nicod E; Reni M; Roux JL; Schlander M; Taylor D; Tomino C; Torrent-Farnell J; Upadhyaya S; Hutchings A; Le Dez L
    Orphanet J Rare Dis; 2017 Mar; 12(1):50. PubMed ID: 28283046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical assessment of belgian reimbursement dossiers of orphan drugs.
    Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
    Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties.
    Pontes C; Fontanet JM; Vives R; Sancho A; Gómez-Valent M; Ríos J; Morros R; Martinalbo J; Posch M; Koch A; Roes K; Oude Rengerink K; Torrent-Farnell J; Torres F
    Orphanet J Rare Dis; 2018 Nov; 13(1):206. PubMed ID: 30442155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel approach to decision making for orphan drugs.
    Decker B; Mlcoch T; Pustovalova A; Dolezal T
    Int J Technol Assess Health Care; 2023 Feb; 39(1):e10. PubMed ID: 36748356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study).
    de Andrés-Nogales F; Cruz E; Calleja MÁ; Delgado O; Gorgas MQ; Espín J; Mestre-Ferrándiz J; Palau F; Ancochea A; Arce R; Domínguez-Hernández R; Casado MÁ;
    Orphanet J Rare Dis; 2021 Apr; 16(1):186. PubMed ID: 33902672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 10. Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
    Brabers AE; Moors EH; van Weely S; de Vrueh RL
    Orphanet J Rare Dis; 2011 Sep; 6():59. PubMed ID: 21892964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The European challenges of funding orphan medicinal products.
    Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
    Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years' multi-stakeholder dialogue on improving access in Europe via MoCA.
    Cavaller-Bellaubi M; Hughes-Wilson W; Kubinová Š; Van de Casteele M; Van Lente EJ; Degortes E; Pontén J; Eichler HG; Le Cam Y; Boselli S; Bucsics A
    Orphanet J Rare Dis; 2023 Jun; 18(1):144. PubMed ID: 37308991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.
    Iskrov GG; Raycheva RD; Stefanov RS
    Folia Med (Plovdiv); 2013; 55(3-4):80-6. PubMed ID: 24712287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.
    Dear JW; Lilitkarntakul P; Webb DJ
    Br J Clin Pharmacol; 2006 Sep; 62(3):264-71. PubMed ID: 16934041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of orphan medicine expenditure in Europe: is it sustainable?
    Mestre-Ferrandiz J; Palaska C; Kelly T; Hutchings A; Parnaby A
    Orphanet J Rare Dis; 2019 Dec; 14(1):287. PubMed ID: 31829218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales.
    Pijeira Perez Y; Wood E; Hughes DA
    Orphanet J Rare Dis; 2023 Nov; 18(1):342. PubMed ID: 37915031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases.
    Annemans L; Makady A
    Orphanet J Rare Dis; 2020 May; 15(1):127. PubMed ID: 32456653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation.
    Mulder J; van Rossum T; Mariz S; Magrelli A; de Boer A; Pasmooij AMG; Stoyanova-Beninska V
    Front Oncol; 2021; 11():809035. PubMed ID: 34988030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [FINANCING OF MEDICINES FOR TREATMENT OF RARE DISEASES OF THE NERVOUS SYSTEM. ORPHAN DRUGS IN RARE NEUROLOGICAL DISEASES].
    Szegedi Márta ; Kosztolányi G; Boncz I; Molnár MJ
    Ideggyogy Sz; 2016 Jan; 69(1-2):37-45. PubMed ID: 26987239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.